Please provide your email address to receive an email when new articles are posted on . Patients receiving tofacitinib had fewer enthesitis relapses following initial resolution after 1 or 3 months.

Patients with psoriatic arthritis with enthesitis are more likely to have severe disease than patients without enthesitis, and they and their physicians are less likely to be satisfied with their ...

Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found. At week 24, 45% of patients ...

The severity of enthesitis in psoriatic arthritis is a potential marker for severe disease and joint damage, a cross-sectional study found. For instance, a 10-unit increase on the Madrid Sonographic ...

Please provide your email address to receive an email when new articles are posted on . In patients with psoriatic arthritis, secukinumab and adalimumab demonstrated similar results regarding ...

The approval was based on data from the 2-year phase 3 JUNIPERA study that evaluated secukinumab in pediatric patients aged 2 to 17 years with a confirmed diagnosis of ERA or JPsA. The Food and Drug ...

R arthritis Several recent studies have shown that a delay in diagnosis of PsA leads to a worse outcome. WASHINGTON, DC—Is there a clinical profile for patients with psoriatic arthritis (PsA) with a ...

No new safety concerns were observed through 16 weeks among pediatric patients with juvenile psoriatic arthritis or enthesitis-related arthritis receiving ixekizumab. Ixekizumab (IXE) demonstrated ...

New research reveals promising data supporting two new drug classes for the treatment of psoriatic arthritis (PsA). The results of two studies presented at the Annual European Congress of Rheumatology ...

ROME — Apremilast (Otezla, Celgene), a new oral option for the treatment of psoriatic arthritis, shows sustained and clinically meaningful improvement in key symptoms of the disease out to 104 weeks, ...

Psoriatic arthritis is commonly misdiagnosed because patients may present with symptoms similar to those with other inflammatory and rheumatologic conditions, according to study findings from Drugs.